PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
8-K Current Report
Filed: March 6, 2026
Health Care
Laboratory Analytical InstrumentsPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Michele Farmer resigning as CAO effective March 21, 2026 — voluntary departure, no severance, no disagreements with company
- • CFO Jim Gibson absorbs principal accounting officer role with no additional compensation change
Item 7.01 · Regulation FD Disclosure
- • Settlement with PGI ends patent litigation; PACB pays $8M in Q1 2026, then $5M/year in Q1 2027–2029 (total minimum $23M)
- • 2027 payment increases by $1M if 2026 revenue ≥$165M, another $1M if ≥$180M — creating a revenue-linked contingent liability up to $25M total
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K Filings
Get deeper insights on PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.